Abstract
Objectives The aim of this study was to investigate time trends in known and undiagnosed diabetes, HbA1c levels, and other cardio-metabolic risk factors in the general population as well as treatment target achievement among those with diabetes.
Design and setting Repeated cross-sectional surveys in the population-based Tromsø Study.
Methods We used age-adjusted generalized estimating equation models to study trends in self-reported and undiagnosed (HbA1c ≥6.5%) diabetes, cardio-metabolic risk factors and the metabolic syndrome in 27281 women and men aged 40-84 years examined in up to four surveys of the Tromsø Study between 1994 and 2016. Further, we analyzed trends in diabetes treatment target achievement.
Results During 1994-2016 diabetes prevalence increased in women (2.3% to 3.9%) and men (2.4% to 5.3%) and in all age-groups, while the proportion of undiagnosed diabetes in women (33% to 20%) and men (37% to 27%) decreased. Blood pressure and total cholesterol decreased, while waist circumference increased in participants with and without diabetes, leading to a relatively stable prevalence of the metabolic syndrome throughout the study period. There was a marginal increase in HbA1c levels among participants without diabetes. Only half of those with diabetes achieved the treatment target of HbA1c ≤7.0%.
Conclusion In the last two decades diabetes prevalence increased, while the proportion of undiagnosed diabetes declined. The prevalence of the metabolic syndrome remained stable throughout, driven by opposing trends with an increase in obesity and a decrease in other cardio-metabolic risk factors. HbA1c treatment target achievement did not improve.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was partly funded by a grant from The Norwegian Diabetes Association. The funder had no involvement in the study design, collection, analysis and interpretation of data, the writing of the manuscript or the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Tromso Study is approved by the Regional Committee of Medical and Health Research Ethics (REC North) and the Norwegian Data Protection Authority.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data referred to in the manuscript were used under license for the current study, and so are not publicly available. The data are available upon application to the Tromso Study: tromsous{at}uit.no.
